Long-Term Follow-up of Alpha-Interferon Treatment of Patients with Chronic Hepatitis B

Hepatology

Volumn 39, Issue 3, 2004, Pages 804-810

  Van Zonneveld, Monika ^a   Honkoop, Pieter ^a   Hansen, Bettina E ^a   Niesters, Hubertus G M ^a   Murad, Sarwa Darwish ^a   De Man, Robert A ^a   Schalm, Solko W ^a   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC HEPATITIS; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EVALUATION; FEMALE; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SEROCONVERSION; SURVIVAL RATE; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 1542724805     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20128     Document Type: Article

References (25)

1. Lee WM. Hepatitis B virus infection. N Eng J Med 1997;337:1733-1745.
2. Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. HEPATOLOGY 1999;30:257-264.
3. Fattovich G. Natural course and prognosis of chronic hepatitis type B. Viral Hep Rev 1996;2:263-276.
4. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. HEPATOLOGY 1988;8:493-496.
5. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990;150:1051-1054.
6. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981;94:744-748.
7. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Eng J Med 1990;323:295-301.
8. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
9. Berk L, Schalm SW, de Man RA, Heytink RA, Berthelot P, Brechot C, Boboc B, et al. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial. J Hepatol 1992;14:305-309.
10. Janssen HL, Berk L, Schalm SW, Heijtink RA, Hess G, Rossol S, Meyer zum Buschenfelde KH, et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. Gut 1992;33:1094-1098.
11. Janssen HL, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of alpha-interferon f or treatment of chronic hepatitis type B. J Hepatol 1993;17(suppl 3):S47-51.
12. Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). HEPATOLOGY 1999;30:238-243.
13. Mutimer D, Naoumov N, Honkoop P, Marinos G, Ahmed M, de Man R, McPhillips P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998;28:923-929.
14. Janssen HL, Berk L, Heijtink RA, ten Kate FJ, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. HEPATOLOGY 1993;17:383-388.
15. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000;46:562-568.
16. Schiff ER, Dienstag JL, Karayalcin S, Grimm IS, Perrillo RP, Husa P, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003;38:818-826.
17. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 2000;38:2897-2901.
18. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Eng J Med 1996;334:1422-1427.
19. Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias JM, Bassendine M, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. J Hepatol 1996;25:803-813.
20. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667.
21. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 1998;5:389-397.
22. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. HEPATOLOGY 1999;29:971-975.
23. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. HEPATOLOGY 2001;34:139-145.
24. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656-666.
25. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). HEPATOLOGY 1997;26:1338-1342.